ID: ALA422159

Max Phase: Preclinical

Molecular Formula: C16H14N4O3

Molecular Weight: 310.31

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(O)c2cc(CNc3ccc(C(=O)O)cc3)ccc2n1

Standard InChI:  InChI=1S/C16H14N4O3/c17-16-19-13-6-1-9(7-12(13)14(21)20-16)8-18-11-4-2-10(3-5-11)15(22)23/h1-7,18H,8H2,(H,22,23)(H3,17,19,20,21)

Standard InChI Key:  OKJTWJFPULDSSA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 310.31

Molecular Weight (Monoisotopic): 310.1066

AlogP: 2.23

#Rotatable Bonds: 4

Polar Surface Area: 121.36

Molecular Species: ACID

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.74

CX Basic pKa: 2.97

CX LogP: 2.30

CX LogD: -0.20

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.58

Np Likeness Score: -0.99

References

1. Crippen GM..  (1980)  Quantitative structure-activity relationships by distance geometry: systematic analysis of dihydrofolate reductase inhibitors.,  23  (6): [PMID:7392027] [10.1021/jm00180a004]

2. Ghose AK, Crippen GM..  (1982)  Quantitative structure-activity relationship by distance geometry: quinazolines as dihydrofolate reductase inhibitors.,  25  (8): [PMID:7120278] [10.1021/jm00350a003]

3. Chen BK, Horváth C, Bertino JR..  (1979)  Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.,  22  (5): [PMID:110930] [10.1021/jm00191a005]

4. Hansch C, Fukunaga JY, Jow PY..  (1977)  Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines.,  20  (1): [PMID:319234] [10.1021/jm00211a020]

Source

Source(1):

• Scientific Literature